Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 41 - Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
Patents for A61P 41 - Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution (3,707)
11/2000
11/16/2000WO2000038665A3 Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
11/16/2000WO2000037025A3 Antibodies to truncated vegf-d and uses thereof
11/16/2000DE19921567A1 Verwendung von Phthalazine-Derivaten Use of derivatives phthalazines
11/16/2000CA2372704A1 Use of phthalazine derivatives
11/09/2000WO2000066130A1 Pharmaceutical composition in unit form containing acetylsalcylic acid and clopidogrel hydrogenosulphate
11/09/2000WO2000066086A1 Anti-inflammatory bioactive glass particulates
11/09/2000WO2000042031A3 Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
11/09/2000WO2000039087A3 Substituted (aminoiminomethyl or aminomethyl)benzoheteroaryl compounds as factor xa inhibitors
11/09/2000WO2000038718A3 Use of matrix metalloproteinase inhibitor together with an antineoplastic agents, optionally also together with radiation, in the treatment of neoplasia
11/09/2000WO2000030668A3 Use of parvovirus capsid particles in the inhibition of cell proliferation and migration
11/09/2000CA2371231A1 Pharmaceutical composition in unit form containing acetylsalicylic acid and clopidogrel hydrogenosulphate
11/08/2000EP1050307A1 CCR4 antagonists in sepsis
11/07/2000US6143797 Use of sodium 2-mercaptoethanesulfonate in surgery
11/06/2000CA2271190A1 Improved method for treating mammals with modified mammalian blood
11/02/2000WO2000064930A2 Tribonectins
11/02/2000WO2000064911A1 Ligands for metabotropic glutamate receptors
11/02/2000WO2000064468A2 Therapeutic compositions and methods for enhancing angiogenesis
11/02/2000WO2000038730A3 Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia
11/02/2000CA2371046A1 Therapeutic compositions and methods for enhancing angiogenesis
11/02/2000CA2367750A1 Tribonectins
10/2000
10/31/2000US6140314 Selective and non-invasive visualization or treatment of vasculature
10/25/2000EP1014998A4 Polymeric compositions
10/25/2000CN1057760C Amino acid substituted benzoylguanidines, process for their preparation, their use and medicament containing them
10/19/2000WO2000061755A2 Secreted human proteins
10/19/2000WO2000061620A1 49 human secreted proteins
10/19/2000WO2000061204A1 Three-dimensional stromal tissue
10/19/2000WO2000035420A3 Stable surgical irrigating solutions
10/19/2000CA2370767A1 49 human secreted proteins
10/18/2000CN1270523A Compositions for lubricating and separating tissues and biological membranes
10/12/2000WO2000059515A2 Immunomodulating polymers
10/12/2000CA2366895A1 Immunomodulating polymers
10/05/2000WO2000058466A2 Protease resistant flint analogs
10/04/2000CN1268366A Changtong inflammation relieving and pain-stopping oral liquor
10/03/2000US6127348 Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
09/2000
09/28/2000WO2000056767A1 46 human secreted proteins
09/28/2000WO2000056350A2 Methods of use of beta 1-integrin inhibitors
09/28/2000WO2000056349A1 Treatment with small peptides to effect antifibrotic activity
09/28/2000WO2000056283A1 Inhibition of matrix metalloproteinases with polymers and pharmaceutical applications thereof
09/28/2000WO2000033822A9 Active ingredient matrix in the form of a biologically resorbable porous non-woven made of collagen fibrils, method for the production and use thereof
09/28/2000CA2367048A1 Treatment with small peptides to effect antifibrotic activity
09/28/2000CA2365223A1 46 human secreted proteins
09/27/2000EP1038528A1 Pentosan polysulfate containing medicament and implant for treating fibrosis
09/21/2000WO2000054762A2 Use of cross linked polysaccharides for the inhibition of angiogenesis
09/21/2000WO2000054757A2 Use of pirenoxine for the protection of corneal tissues in photokeratectomy
09/21/2000WO2000032577A3 Substituted benzo[de]isoquinoline-1,3-diones
09/21/2000WO2000027868A3 Connective tissue growth factor (ctgf) and methods of use
09/21/2000CA2365767A1 Angiogenesis inhibition
09/20/2000CN1267222A Polymeric compositions
09/14/2000WO2000030668A8 Use of parvovirus capsid particles in the inhibition of cell proliferation and migration
08/2000
08/31/2000WO2000050453A1 A novel inhibitor of programmed cell death
08/31/2000WO2000050040A1 Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula
08/31/2000CA2363621A1 A novel inhibitor of programmed cell death
08/31/2000CA2363131A1 Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula
08/30/2000EP1030676A1 Bonding of cartilaginous matrices using isolated chondrocytes
08/30/2000CN1055919C Arylbenzoylguanidin
08/24/2000WO2000025745A3 Irrigation solution and method for inhibition of pain and inflammation
08/16/2000EP1027893A2 Alginate containing medicament and implant for treating fibrosis
08/15/2000US6103694 Method of decreasing radiation of radio-mimetic chemotherapy for hematopoietic pluripotent cell engraftment
08/10/2000WO2000046253A1 Process for the production of multiple cross-linked hyaluronic acid derivatives
08/10/2000WO2000045804A2 Use of a polyanionic polysaccharide solution for the prevention of abscess formation
08/10/2000CA2361572A1 Prevention of abscess formation
08/09/2000EP1024823A1 Prevention and treatment of adhesion formation
08/03/2000WO2000044371A1 2-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmission
08/03/2000WO2000024412A3 Use of vegf-c or vegf-d gene or protein to prevent restenosis
08/03/2000CA2360674A1 2-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmission
07/2000
07/27/2000WO2000012683A9 Stem cells bearing an fgf receptor on the cell surface
07/26/2000EP1021148A1 Composition and method for acceleration of wound and burn healing
07/26/2000EP1021084A1 Solution and process for resuscitation and reparation of ischemically damaged tissue
07/20/2000WO2000042054A1 2,3-o-isopropylidene derivatives of monosaccharides as cell adhesion inhibitors
07/20/2000WO2000042031A2 Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
07/20/2000CA2359986A1 2,3-o-isopropylidene derivatives of monosaccharides as cell adhesion inhibitors
07/20/2000CA2359562A1 Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
07/19/2000CN1260205A Medicine for appendicitis
07/18/2000US6090782 Contacting hematopoietic cells with a stem cell proliferation inhibition amount of a peptide or polypeptide having specific amino acid sequence
07/13/2000WO2000040742A1 Use of the cell's own transport system for transferring nucleic acids across the nuclear membrane
07/13/2000WO2000040612A1 Insulin-like growth factor (igf) i mutant variants
07/13/2000WO2000040597A1 Method and composition for angiogenesis inhibition
07/06/2000WO2000039087A2 Substituted (aminoiminomethyl or aminomethyl)benzoheteroaryl compounds as factor xa inhibitors
07/06/2000WO2000038786A2 Use of cyclooxygenase 2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia
07/06/2000WO2000038730A2 Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia
07/06/2000WO2000038719A1 Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia
07/06/2000WO2000038718A2 Use of matrix metalloproteinase inhibitor together with an antineoplastic agents, optionally also together with radiation, in the treatment of neoplasia
07/06/2000WO2000038717A2 Use of a matrix metalloproteinase inhibitor and radiation as a combined treatment of neoplasia
07/06/2000WO2000038715A2 Use of an integrin antagonist and radiation in the treatment of neoplasia
07/06/2000WO2000038665A2 Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
07/06/2000WO2000011147A9 Inbred mhc-homozygous miniature swine and uses thereof
07/06/2000CA2358047A1 Substituted (aminoiminomethyl or aminomethyl)benzoheteroaryl compounds
07/06/2000CA2356929A1 Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combonation therapy in the treatment of neoplasia
07/06/2000CA2356748A1 Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia
07/06/2000CA2356606A1 Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
07/06/2000CA2356462A1 Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
07/06/2000CA2356459A1 Method of using a matrix metalloproteinase inhibitor and radiation therapy as combination therapy in the treatment of neoplasia
07/06/2000CA2356402A1 Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia
07/06/2000CA2356302A1 Method of using a cyclooxygenase-2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia
07/05/2000EP1014998A1 Polymeric compositions
07/05/2000EP1014995A1 Compositions and methods for preventing restenosis following revascularization procedures
07/04/2000US6083930 Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
06/2000
06/29/2000WO2000037107A2 Use of cyclooxygenase-2 inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
06/29/2000WO2000037025A2 Antibodies to truncated vegf-d and uses thereof
06/29/2000WO2000012683A3 Stem cells bearing an fgf receptor on the cell surface
1 ... 25 26 27 28 29 30 31 32 33 34 35 36 37 38